Skip to main content

Table 3 Demographic data for the eleven results papers

From: Bayesian statistics in the design and analysis of cluster randomised controlled trials and their reporting quality: a methodological systematic review

N (%) unless otherwise stated

Total (N = 11)

Primary (N = 7)

Secondary (N = 4)

Year of publication

 Pre 2005

0 (0.0)

0 (0.0)

0 (0.0)

 2005–2012

6 (54.5)

4 (57.1)

2 (50.0)

 Post 2012

5 (45.5)

3 (42.9)

2 (50.0)

Location of first authora

 UK

2 (18.2)

1 (14.3)

1 (25.0)

 US/Canada

5 (45.5)

4 (57.1)

1 (25.0)

 Europe excl. UK

3 (27.3)

1 (14.3)

2 (50.0)

 Australia/New Zealand

0 (0.0)

0 (0.0)

0 (0.0)

 Africa

2 (18.2)

1 (14.3)

1 (25.0)

 Asia

0 (0.0)

0 (0.0)

0 (0.0)

 Other

0 (0.0)

0 (0.0)

0 (0.0)

Location of studya

 UK

1 (9.1)

0 (0.0)

1 (25.0)

 US/Canada

3 (27.3)

3 (42.9)

0 (0.0)

 Europe excl. UK

4 (36.4)

2 (28.6)

2 (50.0)

 Australia/New Zealand

0 (0.0)

0 (0.0)

0 (0.0)

 Africa

4 (36.4)

2 (28.6)

2 (50.0)

 Asia

0 (0.0)

0 (0.0)

0 (0.0)

 Other

0 (0.0)

0 (0.0)

0 (0.0)

Target sample size; mean (SD) [range]

N/A

N = 3b

1466.7 (1868.6)

[120, 3600]

N/A

Target number of clusters; mean (SD) [range]

N/A

N = 2c

200.0 (198.0)

[60, 340]

N/A

Recruited Sample Size; mean (SD) [range]

N = 11

10898.5 (19816.1)

[116, 66204]

N = 7

2484.6 (3700.1)

[116, 9928]

N = 4

25662.8 (28762.5)

[683, 66204]

Recruited Number of Clusters; mean (SD) [range]

N = 11

58.8 (95.6)

[5, 341]

N = 7

69.1 (121.6)

[5, 341]

N = 4

40.8 (13.2)

[21, 48]

Randomisation unit

 Medical facility

1 (9.1)

1 (14.3)

0 (0.0)

 Village/community/district

6 (54.5)

4 (57.1)

2 (50.0)

 Organisation

1 (9.1)

1 (14.3)

0 (0.0)

 Couple

1 (9.1)

1 (14.3)

0 (0.0)

 Individual

1 (9.1)

0 (0.0)

1 (25.0)

 Working unit (office)

1 (9.1)

0 (0.0)

1 (25.0)

Primary outcome type

 Binary

9 (81.8)

5 (71.4)

4 (100.0)

 Continuous

2 (18.2)

2 (28.6)

0 (0.0)

 Statistician involvement

8 (72.7)

5 (71.4)

3 (75.0)

Statistician association

 Clinical trials unit

1 (12.5)

0 (0.0)

1 (33.3)

 Academic statistical department

7 (87.5)

5 (100.0)

2 (66.6)

 Commercial pharmaceutical company

0 (0.0)

0 (0.0)

0 (0.0)

 Clinical research organisation

0 (0.0)

0 (0.0)

0 (0.0)

 Other

0 (0.0)

0 (0.0)

0 (0.0)

Journal endorsement of CONSORT guidelines

 High

N/A

3 (42.9)

N/A

 Medium

N/A

1 (14.3)

N/A

 Low

N/A

0 (0.0)

N/A

 None

N/A

3 (42.9)

N/A

  1. aOne author was associated with an institution in both Europe and the UK, and the associated study was run across both locations. The denominator used for the calculations is based on the number of papers
  2. bTwo studies specified the number of participants approached but these were not explicitly stated/justified recruitment targets and so were excluded
  3. cFour studies specified the number of clusters approached but these were not explicitly stated/justified recruitment targets and so were excluded
Back to article page

Systematic Reviews

ISSN: 2046-4053